Table 3.
Impact of study design and diagnostic method on the estimation of HI-related protection
| Model name$ | ALL | DES | DIAG | DOR |
|---|---|---|---|---|
| Number of subjects | 5899 | 5899 | 5899 | 3825 |
| Number of flu cases | 1304 | 1304 | 1304 | 612 |
| Parameter Estimates* | ||||
| μα [95% CI] | 2.844 [2.25;3.36] | 2.55 [1.49;3.44] | 2.751 [1.79;3.75] | 1.594 [1.78;6.39] |
| σα [95% CI] | 0.845 [0.44;1.41] | 0.936 [0.49;1.56] | 0.905 [0.45;1.54] | 0.956 [0.23;1.88] |
| μb [95% CI] | 1.299 [1;1.69] | 1.222 [0.8;1.77] | 1.181 [0.75;1.72] | -1.414 [3.59;1.37] |
| σβ [95% CI] | 0.376 [0.1;0.76] | 0.412 [0.1;0.85] | 0.428 [0.14;0.83] | 0.211 [0.02;0.53] |
| Study designa | ||||
| αco [95% CI] | 0.096 [1.23;1.44] | |||
| βco [95% CI] | -0.021 [0.79;0.78] | |||
| αch [95% CI] | 0.577 [0.82;1.97] | |||
| βch [95% CI] | 0.241 [0.54;1.09] | |||
| Diagnosisb | ||||
| αser [95% CI] | 0.091 [1.57;1.54] | |||
| βser [95% CI] | 0.131 [0.58;0.89] | |||
| αili [95% CI] | 0.07 [1.65;1.36] | |||
| βili [95% CI] | 0.415 [0.52;1.45] | |||
| E[λi] [95% CI] | 0.482 [0.41;0.57] | 0.5 [0.43;0.59] | 0.491 [0.42;0.58] | 0.505 [0.38;0.62] |
| E[μi] [95% CI] | 3.116 [2.93;3.26] | 3.115 [2.93;3.26] | 3.112 [2.94;3.26] | 3.168 [2.96;3.33] |
| E[σi] [95% CI] | 0.752 [0.69;0.82] | 0.751 [0.69;0.82] | 0.751 [0.69;0.82] | 0.809 [0.74;0.89] |
| DIC | 4667.0 | 4670.0 | 4669.0 | 2623.0 |
$. ALL: All datasets and no covariate, STRAIN: All datasets + 1 covariate for virus strain (reference category: type A virus), ALL_V: datasets with information on vaccination status, VAC: datasets with information on vaccination status + 1 covariate for vaccination status (reference category: vaccinated), HOB: data reported in Hobson et al. [5], no covariate
* Reported values for each parameter: posterior mean value and 95% credible interval